Document is current
Any future updates will be listed below
-
Authors
Kordowitzki, Pawel https://orcid.org/0000-0002-3344-5060
Ying, Kejun
Beck, Maximilian H.
Velho, Renata Voltolini
Engelbrecht, Charlotte
Sehouli, Jalid
Mechsner, Sylvia
-
Funding
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
- License Information
-
More Information
Article History
Received: 27 March 2026
Accepted: 22 July 2026
First Online: 27 July 2026
Declarations
Ethics approval and consent to participate: The study was approved by the ethics commissions of Charité – Universitätsmedizin Berlin (EA2/266/22 and EA1/150/24). Blood samples from patients were obtained with informed consent, following local institutional review and the Declaration of Helsinki.
Consent for publication: All patients have consented to publish the generated results.
Competing interests: Jalid Sehouli reports research activities by Roche Pharma, AstraZeneca, Bayer, Clovis Oncology, GlaxoSmithKline, Lilly, Iqvia, Mural, and MSD; receiving honoraries by GlaxoSmithKline, PharmaMar, AstraZeneca, Clovis Oncology, Bayer, Roche Pharma, Vifor Pharma, Hexal AG, Novartis Pharma, Eisai, Esteve Pharmaceuticals, Incyte Biosciences, Phytolife Nutrition, JenaPharm, Kyowa Kirin, Oncoinvent AS, Daiichi, Medtronic Covidien, AMGEN, AbbVie, Corcept Therapeutics, Gilead Sciences, and Myriad; and consulting activities for Merck /Pfizer, PharmaMar, Clovis Oncology, AstraZeneca, Roche Pharma, GlaxoSmithKline, MSD, Eisai, Novocure, Oncoinvent, Intuitive Surgical, Seagen, Bayer Vital, Mundipharma, Sanofi‐Aventis Deutschland GmbH, Immunogen, Tubulis GmbH, Daiichi Sankyo, Bristol Myers Squibb, KaryopharmTherapeutics, and Corcept Therapeutics. The remaining authors declared no conflicts of interest.
